Hypokalemia in thiazide-treated systemic hypertension

Am J Cardiol. 1986 Jul 31;58(2):18A-21A. doi: 10.1016/0002-9149(86)90878-7.

Abstract

Potassium supplementation in diuretic-induced hypokalemia (serum potassium less than 3.5 mmol/liter) in patients being treated for hypertension is a common event. In a previous study 40 mmol/day of orally administered potassium was not effective in preventing diuretic-induced hypokalemia in patients who had previously developed hypokalemia while being treated for hypertension with hydrochlorothiazide. In the study reported here dosages as high as 60 to 80 mmol/day of orally administered potassium failed to prevent hypokalemia in 7 of 19 hypertensive patients who were receiving hydrochlorothiazide. Potassium supplementation was compared with the potassium-sparing diuretic amiloride. The study design was open label and subject matched with crossover of therapeutic regimens.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldosterone / blood
  • Amiloride / therapeutic use
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Humans
  • Hydrochlorothiazide / administration & dosage
  • Hydrochlorothiazide / adverse effects*
  • Hydrochlorothiazide / therapeutic use
  • Hypertension / drug therapy*
  • Hypokalemia / chemically induced*
  • Magnesium / blood
  • Potassium / blood
  • Potassium Chloride / administration & dosage
  • Potassium Chloride / therapeutic use
  • Random Allocation
  • Renin / blood

Substances

  • Hydrochlorothiazide
  • Aldosterone
  • Potassium Chloride
  • Amiloride
  • Renin
  • Magnesium
  • Potassium